Related Experiment Video

Updated: May 29, 2025

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.3K

TRIM21-mediated PRMT1 degradation attenuates colorectal cancer malignant progression

Menghan Cao1,2,3, Zhiying Shao2,4, Xingyou Qian2

  • 1Nanjing Medical University, Nanjing, Jiangsu, China.

Cell Death & Disease
|January 31, 2025
PubMed

Insights

Tripartite motif-containing 21 (TRIM21) is reduced in colorectal cancer (CRC), correlating with poor prognosis. TRIM21 suppresses CRC progression by degrading PRMT1, suggesting its potential as a predictive biomarker.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Tripartite motif-containing 21 (TRIM21) is implicated in antiviral and autoimmune responses.
  • The role of TRIM21 in colorectal cancer (CRC) pathogenesis is not well understood.
  • Understanding TRIM21's function in CRC is crucial for identifying new therapeutic targets and biomarkers.

Purpose of the Study:

  • To investigate the expression levels of TRIM21 in colorectal cancer tissues.
  • To elucidate the functional role of TRIM21 in CRC cell proliferation, migration, and metastasis.
  • To determine the potential of TRIM21 as a prognostic biomarker for CRC patients.

Main Methods:

  • Quantitative analysis of TRIM21 expression in primary CRC tissues.
  • In vitro assays to assess the effects of TRIM21 on CRC cell behavior (proliferation, migration, metastasis).
  • Western blotting and ubiquitination assays to investigate the molecular mechanism involving PRMT1.

Main Results:

  • TRIM21 expression was significantly reduced in primary CRC tissues compared to normal tissues.
  • Lower TRIM21 levels were associated with advanced clinicopathological features and shorter patient survival.
  • TRIM21 suppressed CRC cell proliferation, tumorigenesis, migration, and metastasis.
  • TRIM21 promoted the ubiquitination-mediated degradation of PRMT1, thereby inhibiting CRC progression.

Conclusions:

  • TRIM21 is downregulated in colorectal cancer and serves as a potential tumor suppressor.
  • TRIM21 inhibits CRC progression through the promotion of PRMT1 degradation.
  • TRIM21 is a promising predictive biomarker for assessing the prognosis of colorectal cancer patients.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K